“Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028 - PRNewswire” plus 1 more
“Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028 - PRNewswire” plus 1 more |
| Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028 - PRNewswire Posted: 31 Dec 2019 12:30 PM PST DUBLIN, Dec. 31, 2019 /PRNewswire/ -- The "Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028" report has been added to ResearchAndMarkets.com's offering. Human Respiratory Syncytial Virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae. Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization between 2-3 months of age. Severe respiratory disease can manifest as bronchiolitis and pneumonia, which can progress to respiratory failure or death in rare occasions. Respiratory Syncytial Virus (RSV) is also an important cause of hospitalizations and deaths in elderly adults. The Respiratory Syncytial Virus (RSV) market is expected to grow at a compound annual growth rate (CAGR) of 44.7% from US$36.88m in 2018 to US$1.48bn by 2028 across the five growth markets (*5GM - Australia, India, Japan, South Korea and urban China) in the Asia-Pacific (APAC) region. The main driver of growth will be the launch of new products to prevent medically-significant Respiratory Syncytial Virus (RSV) infections, including the first products to be licensed for Respiratory Syncytial Virus (RSV) in India and urban China. The level of unmet need in the Respiratory Syncytial Virus (RSV) marketplace is high in India and urban China, where there are currently no prophylactic or therapeutic options. The launch of the first Respiratory Syncytial Virus (RSV) products in 2023 in urban China and 2024 in India is expected to be a strong driver of growth for the 5GM over the forecast period, especially considering the large potential patient populations in these markets. Research reveals that the current standard of care and only available product for Respiratory Syncytial Virus (RSV), AstraZeneca/AbbVie's Synagis (palivizumab), is likely to be displaced during the forecast period. Synagis is currently the only licensed product in Australia, South Korea and Japan for prevention of Respiratory Syncytial Virus (RSV) infections in young children, but its high price and restrictive label have narrowed its clinical applications to only the highest-risk infants. In addition, the requirement for five monthly injections of Synagis is a substantial barrier to full patient compliance. Sales of Synagis are expected to drop substantially after the launch of AstraZeneca/Sanofi's pipeline candidate mAb MEDI8897 in 2024, which is projected to reach US$629m in annual revenue by 2028. MEDI8897 will also provide the first prophylactic mAb option for patients in India and urban China. It is likely that several first-in-class products for the management of Respiratory Syncytial Virus (RSV) will coexist simultaneously by 2028, including both vaccines and antivirals for treatment of severe or breakthrough Respiratory Syncytial Virus (RSV) infections. However, the global impact of new products in reducing the overall Respiratory Syncytial Virus (RSV) burden will depend on the cost-effectiveness of these drugs, as well as how vaccines are eventually integrated into national immunization policies throughout the 5GM - Australia, India, Japan, South Korea and urban China. The report helps in answering the following question with regards to Respiratory Syncytial Virus (RSV) and its therapeutic market in Asia Pacific.
Scope
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/30hotb About ResearchAndMarkets.com Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. Media Contact: Research and Markets For E.S.T Office Hours Call +1-917-300-0470 U.S. Fax: 646-607-1907 SOURCE Research and Markets  Related Links |
| Posted: 31 Dec 2019 05:07 AM PST  As 2019 comes to a close, the Healio Pulmonology Editors have compiled a list of the most-read articles published this year. Our readers were interested in a new screening algorithm to predict obstructive sleep apnea in pregnant women, the outbreak of vaping-related lung injuries, new treatments and digital tech for asthma, novel therapies approved in 2019 and much more. Childhood asthma linked to family history of cancer Children with a family history of cancer may be more likely to develop asthma, according to research presented at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting. Read more Screening algorithm accurately predicts OSA in pregnant women A new algorithm may help screen pregnant women, particularly African American women, for obstructive sleep apnea, according to a recent study. Read more THC products may be factor in outbreak of vaping-related lung injuries: CDC Products containing tetrahydrocannabinol, or THC, may play a role in the outbreak of lung injuries associated with use of electronic cigarettes, or vaping, CDC and state public health officials announced in late September. Read more As-needed budesonide-formoterol bests albuterol for exacerbation prevention in mild asthma Single combination inhaler treatment with budesonide-formoterol on an as-needed basis, compared with albuterol, more than halved the risk for severe asthma attacks in patients with mild asthma, according to the results of the Novel START trial presented at the American Thoracic Society International Conference. Read more Four novel sepsis phenotypes identified A new study has identified four clinical phenotypes of sepsis that may allow more precise therapy and improve care of critically ill patients. Read more Occupational exposure to disinfectants may raise COPD risk New data published in JAMA Network Open showed that the risk for COPD incidence was higher among nurses who regularly performed cleaning and disinfectant tasks. Read more Novel therapy for IPF shows sustained long-term benefits Patients with idiopathic pulmonary fibrosis treated with a recombinant human pentraxin 2 protein exhibited sustained reductions in decline of FVC and 6-minute walking distance at 76 weeks, according to data presented at the American Thoracic Society International Conference and simultaneously published in The Lancet Respiratory Medicine. Read more Inhaler formulary changes may worsen asthma control in children Switching inhaler types due to insurance formulary changes may lead to reduced lung function in children with asthma, according to data presented at the CHEST Annual Meeting. Read more ROSE: No mortality benefit with early neuromuscular blockade vs. usual care in ARDS A strategy of early neuromuscular blockade with concomitant heavy sedation, compared with usual care, did not result in a significant mortality difference at 90 days in patients with moderate to severe acute respiratory distress syndrome. Read more Study links air pollution to nine causes of death A new study has identified nine specific causes of death that are related to exposure to ambient fine particulate matter air pollution. Read more Triple therapy approved to treat cystic fibrosis The FDA announced it has approved elexacaftor/ivacaftor/tezacaftor, the first triple combination therapy for patients with the most common cystic fibrosis mutation. Read more C-reactive protein testing safely reduces antibiotic use for COPD exacerbations The use of point-of-care testing for C-reactive protein to guide treatment lessened the use of antibiotics for COPD exacerbations without worsening clinical outcomes, according to a study published in The New England Journal of Medicine. Read more INBUILD: Nintedanib slows progression of fibrosing ILD When compared with placebo, nintedanib slowed the annual rate of decline in FVC in patients with progressive fibrosing interstitial lung disease other than idiopathic pulmonary fibrosis, researchers reported at the European Respiratory Society International Congress. Read more Robotic bronchoscopy improves diagnostic yield for peripheral pulmonary nodules When compared with existing technologies, robotic bronchoscopy increased the ability to localize and successfully puncture small peripheral pulmonary nodules, researchers reported. Read more New digital inhaler receives FDA approval for patients with asthma The FDA has approved a combination therapy digital inhaler for treatment of asthma in patients aged 12 years and older, according to a manufacturer press release. Read more |
| You are subscribed to email updates from "respiratory drugs,respiratory failure causes,respiratory failure treatment" - Google News. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
Comments
Post a Comment